{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:50:26Z","timestamp":1784289026346,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005925","name":"Buddhist Tzu Chi Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> Intravesical platelet-rich plasma (PRP) injections have been demonstrated effective in relieving symptoms among patients with interstitial cystitis\/bladder pain syndrome (IC\/BPS). This study compared the clinical efficacy among different injection number, adding solution, and concentrations of PRP.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A total of 63 patients with IC\/BPS were enrolled and randomly allocated to four subgroups who received single high-dose PRP (from 100\u00a0ml whole blood) plus 10\u00a0ml of normal saline or plasma injected over 20 or 40 sites. Patients were followed up at 1, 3, and 6\u00a0months for changes in the IC symptom index (ICSI) and problem index (ICPI), visual analog scale (VAS), global response assessment (GRA), and urodynamic parameters. Furthermore, we compared the clinical outcome with our previous study in a group of 55 IC\/BPS patients who underwent four monthly low-dose PRP (from 50\u00a0ml whole blood) injections.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The result of this study showed significant improvements in IC symptoms (ICSI 11.9 \u00b1 4.4 <jats:italic>vs<\/jats:italic>. 10.2 \u00b1 4.9, <jats:italic>p<\/jats:italic> = 0.009; ICPI 12.3 \u00b1 3.4 <jats:italic>vs<\/jats:italic>. 10.6 \u00b1 4.7, <jats:italic>p<\/jats:italic> = 0.003); VAS (5.46 \u00b1 2.96 <jats:italic>vs<\/jats:italic>. 3.83 \u00b1 3.1, <jats:italic>p<\/jats:italic> 0.000), and maximum flow rate (10.4 \u00b1 4.9 <jats:italic>vs<\/jats:italic>. 17.1 \u00b1 11.5\u00a0ml\/s, <jats:italic>p<\/jats:italic> = 0.000) at 3\u00a0months after single high-dose PRP injection. However, no significant differences in therapeutic results were observed among subgroups, regardless of the added component or injecting site. The improvements of ICSI, ICPI, and GRA at 6\u00a0months were lower in comparison with the results of four low-dose PRP injections. All patients were free of dysuria, urinary retention, or urinary tract infection after PRP treatment.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Intravesical PRP injection is effective for IC\/BPS. The addition of normal saline or plasma and injection site had no influence on therapeutic efficacy. However, the symptom improvement and GRA after a single high-dose PRP injection was lower than that after four low-dose PRP injections 6\u00a0months after the first treatment. Limitation of the study is lack of sham control group.<\/jats:p>","DOI":"10.3389\/fphar.2022.853776","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T18:24:18Z","timestamp":1648405458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis\/Bladder Pain Syndrome\u2014A Comparative Study of Different Injection Number, Additives and Concentrations"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuan-Hong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Fong","family":"Jhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chen","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Hsiang","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The Standardisation of Terminology of Lower Urinary Tract Function: Report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"B2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/scrt218","article-title":"Platelet-rich Plasma Preparation for Regenerative Medicine: Optimization and Quantification of Cytokines and Growth Factors","volume":"4","author":"Amable","year":"2013","journal-title":"Stem Cel Res Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41598-018-19419-6","article-title":"An Optimised Protocol for Platelet-Rich Plasma Preparation to Improve its Angiogenic and Regenerative Properties","volume":"8","author":"Etulain","year":"2018","journal-title":"Sci. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1080\/09537104.2018.1430357","article-title":"Platelets in Wound Healing and Regenerative Medicine","volume":"29","author":"Etulain","year":"2018","journal-title":"Platelets"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","article-title":"Diagnosis and Treatment of Interstitial Cystitis\/Bladder Pain Syndrome: AUA Guideline Amendment","volume":"193","author":"Hanno","year":"2015","journal-title":"J. Urol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/s0090-4295(01)01112-8","article-title":"Clinical Highlights of the National Institute of Diabetes and Digestive and Kidney Diseases\/Interstitial Cystitis Association Scientific Conference on Interstitial Cystitis","volume":"57","author":"Hanno","year":"2001","journal-title":"Urology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/iju.14234","article-title":"Clinical Guidelines for Interstitial Cystitis\/bladder Pain Syndrome","volume":"27","author":"Homma","year":"2020","journal-title":"Int. J. Urol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.5213\/inj.2142100.050","article-title":"Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients with Interstitial Cystitis\/bladder Pain Syndrome after Intravesical Platelet-Rich Plasma Injection","volume":"26","author":"Jhang","year":"2022","journal-title":"Int. Neurourol J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/JU.0000000000001334","article-title":"Clinical Relevance of Bladder Histopathological Findings and Their Impact on Treatment Outcomes Among Patients with Interstitial Cystitis\/Bladder Pain Syndrome: An Investigation of the European Society for the Study of Interstitial Cystitis Histopathological Classification","volume":"205","author":"Jhang","year":"2021","journal-title":"J. Urol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/iju.14585","article-title":"Decreased Urothelial Cytoskeleton and Cell Proliferation Protein Expression Suggest Interstitial Cystitis\/bladder Pain Syndrome Patients with Hunner's Lesion and Grade 3 Glomerulation Might Be Different from Other Types of Patients","volume":"28","author":"Jhang","year":"2021","journal-title":"Int. J. Urol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/nau.23898","article-title":"Intravesical Injections of Platelet-Rich Plasma Is Effective and Safe in Treatment of Interstitial Cystitis Refractory to Conventional Treatment-A Prospective Clinical Trial","volume":"38","author":"Jhang","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"B12","doi-asserted-by":"publisher","first-page":"O42","DOI":"10.1111\/luts.12212","article-title":"Repeated Intravesical Injections of Platelet-Rich Plasma Are Effective in the Treatment of Interstitial Cystitis: a Case Control Pilot Study","volume":"11","author":"Jhang","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"B13","doi-asserted-by":"publisher","first-page":"F1391","DOI":"10.1152\/ajprenal.00051.2020","article-title":"Urine Cytokines as Biomarkers for Diagnosing Interstitial Cystitis\/bladder Pain Syndrome and Mapping its Clinical Characteristics","volume":"318","author":"Jiang","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"15218","DOI":"10.1038\/s41598-020-72292-0","article-title":"Repeated Intravesical Injections of Platelet-Rich Plasma Improve Symptoms and Alter Urinary Functional Proteins in Patients with Refractory Interstitial Cystitis","volume":"10","author":"Jiang","year":"2020","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4103\/tcmj.tcmj_92_19","article-title":"Therapeutic Potential of Intravesical Injections of Platelet-Rich Plasma in the Treatment of Lower Urinary Tract Disorders Due to Regenerative Deficiency","volume":"31","author":"Ke","year":"2019","journal-title":"Tzu Chi Med. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1016\/j.cellsig.2008.06.004","article-title":"Cell Signaling in Interstitial Cystitis\/painful Bladder Syndrome","volume":"20","author":"Keay","year":"2008","journal-title":"Cell Signal"},{"key":"B17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s12035-013-8494-7","article-title":"Platelet-rich Plasma and the Elimination of Neuropathic Pain","volume":"48","author":"Kuffler","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.arthro.2017.11.035","article-title":"Growth Factors Levels Determine Efficacy of Platelets Rich Plasma Injection in Knee Osteoarthritis: A Randomized Double Blind Noninferiority Trial Compared with Viscosupplementation","volume":"34","author":"Louis","year":"2018","journal-title":"Arthroscopy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/s0090-4295(01)01126-8","article-title":"Psychometric Validation of the O'leary-Sant Interstitial Cystitis Symptom index in a Clinical Trial of Pentosan Polysulfate Sodium","volume":"57","author":"Lubeck","year":"2001","journal-title":"Urology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3109\/09537104.2016.1143922","article-title":"Cytokine, Chemokine, and Growth Factor Profile of Platelet-Rich Plasma","volume":"27","author":"Mussano","year":"2016","journal-title":"Platelets"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/s0022-5347(01)63178-1","article-title":"The Role of Urinary Potassium in the Pathogenesis and Diagnosis of Interstitial Cystitis","volume":"159","author":"Parsons","year":"1998","journal-title":"J. Urol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1464-410X.2010.09843.x","article-title":"The Role of a Leaky Epithelium and Potassium in the Generation of Bladder Symptoms in Interstitial Cystitis\/overactive Bladder, Urethral Syndrome, Prostatitis and Gynaecological Chronic Pelvic Pain","volume":"107","author":"Parsons","year":"2011","journal-title":"BJU Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1524-475X.2011.00740.x","article-title":"Platelet-rich Fibrin Matrix Improves Wound Angiogenesis via Inducing Endothelial Cell Proliferation","volume":"19","author":"Roy","year":"2011","journal-title":"Wound Repair Regen."},{"key":"B24","doi-asserted-by":"publisher","first-page":"E136","DOI":"10.1111\/j.1464-410X.2010.09911.x","article-title":"Higher Levels of Cell Apoptosis and Abnormal E-Cadherin Expression in the Urothelium Are Associated with Inflammation in Patients with Interstitial Cystitis\/painful Bladder Syndrome","volume":"108","author":"Shie","year":"2011","journal-title":"BJU Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"484.e7","DOI":"10.1016\/j.urology.2011.09.049","article-title":"Increased Cell Apoptosis of Urothelium Mediated by Inflammation in Interstitial Cystitis\/painful Bladder Syndrome","volume":"79","author":"Shie","year":"2012","journal-title":"Urology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3390\/toxins11110676","article-title":"Predictive Factors for a Satisfactory Treatment Outcome with Intravesical Botulinum Toxin A Injection in Patients with Interstitial Cystitis\/Bladder Pain Syndrome","volume":"11","author":"Wang","year":"2019","journal-title":"Toxins (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41598-020-80252-x","article-title":"Cystoscopic Hydrodistention Characteristics Provide Clinical and Long-Term Prognostic Features of Interstitial Cystitis after Treatment","volume":"11","author":"Yu","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.853776\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T18:24:22Z","timestamp":1648405462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.853776\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":27,"alternative-id":["10.3389\/fphar.2022.853776"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.853776","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"article-number":"853776"}}